An Updated Review of the Management of Chronic Heart Failure in Patients with Chronic Kidney Disease.

Rev Cardiovasc Med · 2024 · PMC11264008 · PMID 39076544

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.1900

boldest claim

The sentences

narrowly missed statistical significancep = 0.06so close (0.05 < p ≤ 0.1)

4.2.3 ARNI in HFpEF The PARAGON-HF trial evaluated Sacubitril/valsartan vs valsartan in 4822 patients with HFpEF, and found reduced rates of the composite primary outcome of total hospitalisations for HF and death from cardiovascular causes (rate ratio 0.87), albeit this narrowly missed statistical significance (95% CI 0.75–1.01; p = 0.06) [ 29 ].

also in 72 other papers

failed to reach significancep = 0.19not close (p > 0.1)

More recently, the Ferric Carboxymaltose in Heart Failure With Iron Deficiency (HEART-FID) study investigating IV iron in 3065 patients with HFrEF and iron deficiency, failed to reach significance for its primary endpoint (composite of all-cause mortality, HF hospitalisation or change in 6-minute walking distance), p = 0.19 [ 214 ].

also in 794 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.